©2024 Stanford Medicine
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Not Recruiting
Trial ID: NCT03292406
Purpose
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel
vs. placebo for early stage CTCL (IA, IB, or IIA).
Official Title
A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA
Stanford Investigator(s)
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Michael Khodadoust
Assistant Professor of Medicine (Oncology) and of Dermatology
Eligibility
Inclusion Criteria:
- Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months
- Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3
distinct lesions
Exclusion Criteria:
- CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary
cells or CD8+ or large cell transformation or Progressive CTCL
- History of autoimmune disease
- Laboratory test values at screening outside of the normal range and judged clinically
significant by the investigator
- Current participation in another clinical trial of a drug or device or past
participation within 4 weeks before Baseline or participant is in exclusion period
from a previous clinical trial
Intervention(s):
drug: Placebo
drug: CD11301 0.03%
drug: CD11301 0.06%
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sydney Yee
650-721-6118